Evidence map›Paper›PMID 34887627›Full record

ArticleWorld journal of gastroenterology2021

Over-feeding the gut microbiome: A scoping review on health implications and therapeutic perspectives.

Monica Barone, Federica D'Amico, Marco Fabbrini, Simone Rampelli, Patrizia Brigidi, Silvia Turroni

Open access · bronzeAbstract readScoping Review
In one paragraph

Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Monica BaroneMicrobiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40138, Italy.
Federica D'AmicoMicrobiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40138, Italy.
Marco FabbriniMicrobiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40138, Italy.
Simone RampelliUnit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy.
Patrizia BrigidiMicrobiomics Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40138, Italy.
Silvia TurroniUnit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, University of Bologna, Bologna 40126, Italy. silvia.turroni@unibo.it.
University of Bologna · ITJackson and Tull (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human gut microbiome has gained increasing attention over the past two decades. Several findings have shown that this complex and dynamic microbial ecosystem can contribute to the maintenance of host health or, when subject to imbalances, to the pathogenesis of various enteric and non-enteric diseases. This scoping review summarizes the current knowledge on how the gut microbiota and microbially-derived compounds affect host metabolism, especially in the context of obesity and related disorders. Examples of microbiome-based targeted intervention strategies that aim to restore and maintain an eubiotic layout are then discussed. Adjuvant therapeutic interventions to alleviate obesity and associated comorbidities are traditionally based on diet modulation and the supplementation of prebiotics, probiotics and synbiotics. However, these approaches have shown only moderate ability to induce sustained changes in the gut microbial ecosystem, making the development of innovative and tailored microbiome-based intervention strategies of utmost importance in clinical practice. In this regard, the administration of next-generation probiotics and engineered microbiomes has shown promising results, together with more radical intervention strategies based on the replacement of the dysbiotic ecosystem by means of fecal microbiota transplantation from healthy donors or with the introduction of synthetic communities specifically designed to achieve the desired therapeutic outcome. Finally, we provide a perspective for future translational investigations through the implementation of bioinformatics approaches, including machine and deep learning, to predict health risks and therapeutic outcomes.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaSynbioticsDysbiosisHumansPrebioticsPrebioticsDeep learningFecal microbiota transplantationGut microbiomeMicrobial metabolitesNext-generation probioticsObesity

Identifiers

PMID34887627
PMCPMC8613651
OpenAlexW3213703066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.